Navigation Links
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
Date:8/23/2010

PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

The grant will be used  to defray a significant portion of the costs associated with the conduct of the Company's ongoing, confirmatory, Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host-Disease (GI GVHD).  This trial, also referred to as the SUPPORTS protocol (Sparing Unnecessary Prednisone Phase 3 orBec® Randomized Treatment Study), will enroll an estimated 166 subjects to confirm the clinically meaningful endpoints observed in previous Phase 2 and Phase 3 clinical studies. The primary endpoint in the SUPPORTS protocol is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment).  The Phase 3 study includes major stem cell transplantation centers in the United States, Europe and Australia, and is expected to complete in the first half of 2011.

"We are grateful to have been awarded this significant grant to support our ongoing confirmatory Phase 3 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We believe the award is a validation of the design of our Phase 3 trial and a clear indicator of the importance of orBec® and its potential application in the treatment
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... Amgen (Nasdaq: AMGN ) today announced ... had significantly greater adherence, compliance, and persistence during ... oral bisphosphonate commonly used to treat osteoporosis. ... compliance (a measure of how well patients follow ...
... March 23, 2011 NephRx Corporation today announced issuance ... novel growth factor peptide NX002 as a potential treatment ... NX002 may have applications in acute and chronic diseases ... colitis.  It has been shown to stimulate the growth ...
Cached Medicine Technology:Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 2Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 3Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 4Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 5Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 6Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 7Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 8Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 9Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 10Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 11NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... Orlando, Florida (PRWEB) September 16, 2014 These ... the last 3 years to receive up to $10,000 in ... This program, as well as other state and federal programs, ... have to be paid back until you sell or move ... loan is a 0% interest loan. There are no monthly ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... WASHINGTON, DC September 14, 2014 ... of everolimus-eluting stents (EES) and drug-eluting balloons ... drug-eluting stents found that EES provided superior ... outcomes. , Findings were reported today ... (TCT) scientific symposium. Sponsored by the Cardiovascular ...
(Date:9/16/2014)... absorbs the right balance of nitrogen, phosphorus and potassium ... Kansas State University study finds. , A review of ... and other regions showed that high yields were linked ... key nutrients at specific ratios - nitrogen and phosphorus ... at a ratio of 1-to-1. These nutrient uptake ratios ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3
... proteins CCSA-3 and CCSA-4, present in blood that accurately ... used to develop a blood test to identify ... a team of researchers led by Robert Getzenberg at ... proteins were first discovered by Getzenberg and colleagues at ...
... a tough task to answer who has the best pair of ... has pinned down the top ten beauties with the hottest legs. ... with the sexiest pair of legs, reports The Sun. ... the top slot. ,American R and B singer Beyonce ...
... socialite Paris Hilton has been getting a princess' treatment in ... to inmates, the 26-year-old is living in 'Lean Cuisine' style ... nuggets and fish that others would never get. ... of the women's jail in Lynwood, California, from a Los ...
... in daisy gravy, carnation and herb salad, nasturtium sauce -- ... the plate . ,"Flowers have been used for ... very secondary way", culinary historian Patrick Rambourg told AFP. "In ... the floor during banquets to perfume the room." , ...
... amended a law to ban circuses from importing or ... of animal rights, a legislator said Friday . ... Thursday, all imports and exports of animals such as ... are needed for research, said Tien Chiu-chin, of the ...
... links between alcohol, drugs and risky sexual behaviour are ... a government advisory body report said Friday . ... in the last 12 years, and media coverage of ... Independent Advisory Group on Sexual Health and HIV said. ...
Cached Medicine News:Health News:Flower-power on a Plate in Paris 2Health News:Drink and Drugs 'fuel British Sexual Health Crisis' 2
... reagent once reconstituted offers the laboratory all ... help maximize laboratory productivity, minimize operator error ... patented technology of the Infinity Urea (Nitrogen) ... and stability once reconstituted that will minimize ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... Triglycerides powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: